All In Biotech

Drug Trial Radar · NCT04718181

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Risdiplam - A Phase I, Open-Label, Multi-Period Crossover Study to Investigate the Safety, Food Effect, Bioavailability and Bioequivalence of Oral Doses of Two Different Formulations in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Feb 1, 2021

Primary completion

Jan 28, 2023

Study completion Jan 28, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is a randomized, single oral dose, crossover study in up to three parts to investigate the relative bioavailability and bioequivalence of two different formulations of risdiplam 5 mg (dispersible tablets) versus the current risdiplam oral solution formulation in healthy male and female participants. The effect of food on these two dispersible tablets and the current oral solution will be studied, as well as the effect of omeprazole on the dispersible tablets.

Conditions

  • Muscular Atrophy, Spinal

Interventions

  • risdiplamDrug

    Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.

  • omeprazoleDrug

    Omeprazole will be administered orally as a capsule at a dose of 40 mg per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Plasma Concentration of Risdiplam in Cohorts A and BTime frame: Day 1 to Day 7 in Periods 1-5
  2. Part 1: Plasma Concentration of Risdiplam in Fed and Fasted States in Cohort ETime frame: Day 1 to Day 7 in Period 1 and Period 2
  3. Part 1: Plasma Concentration of Risdiplam in Cohorts C and DTime frame: Period 1: Day 1 to Day 7; Period 2: Day 1 to Day 13
  4. Parts 2 and 3: Plasma Concentration of RisdiplamTime frame: Day 1 to Day 11 in Periods 1-4

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Daytona Beach Clinical Rsch Unit

    Daytona Beach, Florida

  • QPS- Springfield

    Springfield, Missouri

  • Dallas Clinical Research Unit

    Dallas, Texas

  • Covance Clinical Research Unit, Inc

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.